Merck & Co., Inc. (MRK)
Pharmaceutical Preparations · Pharmaceutical Preparations · NYSE
$135.17
-0.59%
Investingg Score
59.3 / 100
Hold
Business overview
- Free cash flow margin of 19%
This robust cash generation indicates solid operational efficiency in converting revenue into cash.
Financial health
- Balance Sheet pillar score of 44
This moderate score reflects standard capital structure considerations with inherent uncertainty regarding debt coverage due to unavailable detailed metrics.
- Gross Margin
- Data unavailable
- Operating Margin
- Data unavailable
- Current Ratio
- 1.5x
- Debt / Equity
- 0.89
- Free Cash Flow (TTM)
- $12.4B
- Interest Coverage
- Data unavailable
Valuation
- Price-to-sales ratio of 0
- Valuation pillar score of 61
Data unavailable for P/E ratio, EV-to-EBITDA, and FCF yield creates uncertainty in determining the absolute valuation attractiveness.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 0.0x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Slow year-over-year revenue growth of 1.3% indicates limited near-term top-line catalysts.
- Multiple key valuation metrics such as P/E and EV-to-EBITDA are unavailable, increasing valuation uncertainty.
- A technical RSI of 67.93 nears the overbought threshold, posing potential short-term pullback risks.
Market cap $0 · data as of 2026-08-18
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze MRK with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.